2006
DOI: 10.1016/j.jhep.2006.02.018
|View full text |Cite
|
Sign up to set email alerts
|

Feasibility and safety of G-CSF administration to induce bone marrow-derived cells mobilization in patients with end stage liver disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

11
88
3
2

Year Published

2007
2007
2018
2018

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 151 publications
(104 citation statements)
references
References 39 publications
11
88
3
2
Order By: Relevance
“…Our findings therefore highlight a therapeutic means by which these host DRs can be directly stimulated and we propose this pathway as a possible mechanism by which autologous BMC therapy may be beneficial in human liver disease. Animal models of BMC therapy for liver disease and clinical autologous BMC therapy studies are underway with encouraging preliminary results (2,(28)(29)(30). A recent report by our group has shown that a single portal vein injection of macrophages significantly reduces fibrosis in a model of chronic liver injury.…”
Section: Discussionmentioning
confidence: 99%
“…Our findings therefore highlight a therapeutic means by which these host DRs can be directly stimulated and we propose this pathway as a possible mechanism by which autologous BMC therapy may be beneficial in human liver disease. Animal models of BMC therapy for liver disease and clinical autologous BMC therapy studies are underway with encouraging preliminary results (2,(28)(29)(30). A recent report by our group has shown that a single portal vein injection of macrophages significantly reduces fibrosis in a model of chronic liver injury.…”
Section: Discussionmentioning
confidence: 99%
“…18 Finally, G-CSF administration was able to induce BMC mobilization in cirrhotic patients, and a clinical improvement was registered in about 50% of treated individuals. 25 However, it remains unclear if G-CSF acts mainly by recruiting BMCs, or if it acts locally to facilitate the endogenous hepatic restoration program. Indeed, in the previously cited studies, G-CSF administration significantly accelerated the regeneration processes.…”
Section: Discussionmentioning
confidence: 99%
“…In a clinical trial, 8 patients affected by severe liver cirrhosis were administered G-CSF and the treatment was well tolerated in all the patients during a follow-up of 8 months, and mobilization of bone marrow stem cells co-expressing epithelial and stem markers was noted [15,16] . Two independent studies on a group of 24 patients and 18 patients [17,18] with severe liver cirrhosis resulted in a dose-dependent mobilization of good CD34+/CD133+ bone marrow stem cells and proved that the procedure was safe, but did not achieve any significant clinical improvement.…”
Section: In Situ Mobilization Of Bone Marrow Cells To the Livermentioning
confidence: 99%